Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of ...
2 Monster Stocks in the Making
There might still be time to get in on the ground floor.
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - Avenue Therapeutics ( OTC:ATXI ) , Axsome Therapeutics ( NASDAQ:AXSM )
MIAMI, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Avenue Therapeutics, Inc. ( OTC:ATXI ) ( "Avenue" or the "Company" ) , a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic ...
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy - Avenue Therapeutics ( OTC:ATXI ) , Axsome Therapeutics ( NASDAQ:AXSM )
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome's broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
uniQure ( QURE ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
uniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Therapeutics ( AXSM ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Therapeutics to Participate in Upcoming Investor Conferences - Axsome Therapeutics ( NASDAQ:AXSM )
NEW YORK, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced that it will participate in the following upcoming investor conferences in ...
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community - Axsome Therapeutics ( NASDAQ:AXSM )
NEW YORK, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced it is recognizing Mental Illness Awareness Week ( MIAW ) alongside the national ...
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - Axsome Therapeutics ( NASDAQ:AXSM )
NEW YORK, Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, ...
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
NEW YORK, Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, ...
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Both should have significant catalysts by the end of the decade.
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstructive sleep apnea Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer's disease agitation, ...
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss - Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - DocGo ( NASDAQ:DCGO ) , Axsome Therapeutics ( NASDAQ:AXSM )
SAN DIEGO, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: General Motors Company GM, DocGo Inc. DCGO, The Estée Lauder Companies Inc. EL, and Axsome Therapeutics, Inc. AXSM.
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years
Both companies have made significant progress in recent years.
Why Is Axsome ( AXSM ) Up 19.2% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced that it will participate in the following upcoming investor conferences in ...
What's Going On With Tonix Pharma Stock Monday? - Tonix Pharmaceuticals ( NASDAQ:TNXP )
Tonmya reduced daily pain scores in Phase 3 trials of nearly 1,000 patients. Tonix ended June with $125.3 million cash, funding operations into Q3 2026. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more.
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - Axsome Therapeutics ( NASDAQ:AXSM )
Axsome Therapeutics, Inc. AXSM reported better-than-expected second-quarter financial results on Monday. Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share.
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Axsome Therapeutics ( AXSM ) Reports Q2 Loss, Beats Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Axsome ( AXSM ) Q2 Revenue Soars 72%
Axsome Therapeutics ( NASDAQ:AXSM ) , a biopharmaceutical company focused on central nervous system ( CNS ) disorders, released its earnings on August 4, 2025. The company reported GAAP revenue of $150.0 million, up 72% compared to the prior year period, and a net loss per share of $ ( 0.97 ) ( ...
Amgen ( AMGN ) Reports Next Week: Wall Street Expects Earnings Growth
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Therapeutics ( AXSM ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Should you invest in stocks right now? Some might be hesitant to do so because of the volatility broader equities have faced this year. Others understand that the stock market generates excellent returns over the long run, regardless of short-term uncertainty.I firmly belong to the second camp.
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses ...
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - Axsome Therapeutics ( NASDAQ:AXSM )
Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company to webcast its R&D Day event today at 11:00 AM Eastern
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
NEW YORK, July 09, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, ...
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 - Axsome Therapeutics ( NASDAQ:AXSM )
NEW YORK, July 09, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. AXSM, a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, ...
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
NEW YORK, June 20, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today is joining with the Alzheimer's disease advocacy community to raise awareness of the ...
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® ( meloxicam and rizatriptan ) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society ( AHS ) - Axsome Therapeutics ( NASDAQ:AXSM )
NEW YORK, June 18, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc.
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders - Axsome Therapeutics ( NASDAQ:AXSM )
NEW YORK, June 16, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. AXSM, a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, is proud to recognize Migraine and Headache Awareness Month alongside the Association of Migraine Disorders.
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
NEW YORK, June 11, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and ...
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 - Axsome Therapeutics ( NASDAQ:AXSM )
NEW YORK, June 11, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc.
Axsome Therapeutics Announces Availability of SYMBRAVO® ( meloxicam and rizatriptan ) for the Acute Treatment of Migraine with or without Aura in Adults - Axsome Therapeutics ( NASDAQ:AXSM )
SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that addresses multiple pathways underlying a migraine attack SYMBRAVO On My Side offers comprehensive patient support services including access and prescription drug support
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required - Axsome Therapeutics ( NASDAQ:AXSM )
FDA rejects AXS-14 NDA citing issues with one of the two key clinical trials. Axsome to initiate new trial in late 2025; fibromyalgia drug launch now seen in 2028. Get access to the leaderboards pointing to tomorrow's biggest stock movers. The U.S.
Axsome Therapeutics Provides Update on the New Drug Application ( NDA ) for AXS-14 for the Management of Fibromyalgia
NEW YORK, June 09, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced it has received a Refusal to File ( RTF ) letter from the U.S.
2 Soaring Stocks Wth More Upside Potential
Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after massive gains -- provided there is plenty of upside left.
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss - Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - DocGo ( NASDAQ:DCGO ) , Axsome Therapeutics ( NASDAQ:AXSM )
SAN DIEGO, June 04, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: General Motors Company GM, DocGo Inc. DCGO, The Estée Lauder Companies Inc. EL, and Axsome Therapeutics, Inc. AXSM.
Why Is Axsome ( AXSM ) Down 1.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced that it will participate in three upcoming investor conferences in June: ...
Why Is Teva Stock Trading Higher On Tuesday? - Teva Pharmaceutical Indus ( NYSE:TEVA )
BD9 blocks both TSLP and IL-13, two major drivers of TH2 inflammation. Biolojic to receive milestone payments tied to BD9 development progress. Discover how Matt Maley trades sharp reversals-live this Wednesday, May 28 at 6 PM ET. Save your free seat now.
Axsome Therapeutics Settles SUNOSI® ( solriamfetol ) Patent Litigation with Hetero Labs Ltd.
NEW YORK, May 27, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) ( Axsome ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. ...
Axsome Therapeutics Settles SUNOSI® ( solriamfetol ) Patent Litigation with Hetero Labs Ltd. - Axsome Therapeutics ( NASDAQ:AXSM )
NEW YORK, May 27, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc.
3 High-Flying Stocks That Could Soar Even More
Many investors love the "big mo." That's short for "big momentum." Stocks that are on a roll often keep the good times going.Three Fool.com contributors think they've found high-flying biotech stocks that could soar even more.
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Explore the exciting world of Axsome Therapeutics ( NASDAQ: AXSM ) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of April 9, 2025.
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss - Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - DocGo ( NASDAQ:DCGO ) , Axsome Therapeutics ( NASDAQ:AXSM )
SAN DIEGO, May 14, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: General Motors Company GM, DocGo Inc. DCGO, The Estée Lauder Companies Inc. EL, and Axsome Therapeutics, Inc. AXSM.
